28th Annual North American Cystic Fibrosis Conference

S11: INF/MIC: Multiple Inhaled Antibiotics: Multiple Therapeutic Considerations

Oct 10, 2014 10:30am ‐ Oct 10, 2014 12:20pm

Standard: $49.99


Suppressive antibiotic treatment of CF patients with chronic P. aeruginosa airway infection is the standard of care in Europe and North America. With the recent inhaled aztreonam approval, there are now three antipseudomonal antibiotic classes that are readily available and commonly utilized to manage chronic P. aeruginosa airway infections: polymyxins (colistimethate), aminoglycosides (gentamicin, tobramycin) and beta lactams (aztreonam). These agents have all been studied and developed as monotherapies, but there is growing interest in the use of these agents in various combinations in individual patients to improve outcomes and extend the period of efficacy of suppressive treatment.


You must be logged in and own this session in order to post comments.